CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (287.8)	$ 879.4	$ (863.6)
Other comprehensive loss
Foreign currency translation adjustment	(646.7)	(717.8)	(50.5)
Unrealized gain on equity method investment, net of tax:
Arising in period	0.0	51.3	0.0
Reclassification to net income (loss)	0.0	(51.3)	0.0
Net unrealized holding gain on available-for-sale equity securities:
Arising in period	0.0	1.8	3.6
Reclassification to net income (loss)	0.0	(1.8)	(4.0)
Other comprehensive (loss) income	(646.7)	(717.8)	(50.9)
Pension and postretirement benefit plan adjustments:
Newly established prior service credit	0.0	29.4	27.9
Net actuarial gain (loss) arising during the year	20.8	(127.3)	24.5
Amortization of prior service credit	(3.1)	(2.5)	0.0
Amortization or settlement recognition of net loss	2.7	0.9	0.6
Income tax (expense) benefit	(2.6)	27.4	(15.4)
Currency impact	(0.6)	5.2	0.2
Total pension and postretirement benefit plan adjustments	17.2	(66.9)	37.8
Other comprehensive loss	(629.5)	(784.7)	(13.1)
Comprehensive (loss) income	(917.3)	94.7	(876.7)
Less: Comprehensive income (loss) attributable to noncontrolling interest	0.1	(2.9)	2.8
Comprehensive (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (917.4)	$ 97.6	$ (879.5)